Full-Time

Director – Pharmacovigilance

Posted on 8/7/2024

4D Molecular Therapeutics

4D Molecular Therapeutics

201-500 employees

Develops gene therapies for genetic diseases

Biotechnology
Healthcare

Compensation Overview

$210k - $270kAnnually

Senior

Oakland, CA, USA

Category
Healthcare Administration & Support
Medical, Clinical & Veterinary
Required Skills
Communications
Management
Requirements
  • MD, PharmD., RN, BSN, Nurse Practitioner, Pharmacist or related degree with at least 5+ years pharmaceutical industry, pharmaceutical industry safety surveillance, or applicable clinical/medical experience required.
  • Demonstrated knowledge of domestic and international ADE reporting regulations per guidelines and follow timelines as necessary for regulatory reporting purposes.
  • Demonstrated knowledge and proficiency with drug safety databases (i.e. ARISg or ARGUS)
  • Proficiency with standard office skills and standard desktop computing programs
  • Excellent oral and written communication skills with excellent interpersonal skills and willingness to work in a team environment, cross functionally, and work with multiregional organizations.
  • Highly organized and demonstrates understanding of workflow prioritization.
  • Ability to multitask and triage as needed with the ability to work independently, under pressure, demonstrating initiative and flexibility.
  • Excellent understanding of clinical trial methodology, GCP and medical terminology
  • Attention to detail and quality focused with strong technical and problem-solving skills
  • Strong organizational and project management skills
  • Strong communication skills and the ability to operate effectively in an international environment
  • Excellent understanding of physiology, pharmacology, clinical study objectives, and the drug development process
  • Strong computer skills including, but not limited to, creation of spreadsheets, templates, presentations and working with safety database applications.
Responsibilities
  • Act as safety leader with responsibility for signal detection and assessment activities for 4DMT products. Example:
  • Signal summary reports;
  • Tracking and using safety database tools for aggregating safety data;
  • Leading cross functional teams to assess safety signals;
  • Creation of action plans to mitigate/manage product risks;
  • Responding to safety associated Health Authority requests;
  • Development and maintenance of product Risk Management Plans (RMP);
  • Monitor the safety profile of delegated products and recommend appropriate action including labeling amendments and risk management programs when warranted assess product specific adverse event information to determine required action based on internal policies;
  • Providing medical assessment as relevant.
  • Participation in maintaining and upgrading pharmacovigilance processes. These may include MedDRA maintenance, PV systems policies, and implementation of new regional and cross-regional PV regulations.
  • Ensures corporate compliance with domestic and international adverse event and safety issue reporting requirements for delegated products.
  • Prepare safety-related sections and associated documentation for clinical and regulatory documents (i.e. clinical study protocols, clinical study final reports, IND annual reports, integrated summaries of safety, annual safety reports, Investigator Brochures, Development Safety Update Reports (DSUR), and Annual safety update reports (ASUR), and other aggregate reports).
  • Review ICFs, clinical study non-serious adverse event line listings and other study related documents containing safety information.
  • May assist with approving, reviewing, and contributing to publications (abstracts, posters, papers) for scientific meetings/journals.
  • Assists with contributing to safety components of strategic documents and to development of Target Product Profile (TPP).
  • Act as the safety liaison/resource on study project teams for safety related issues relating to clinical development.
  • Supervise PV activities and personnel related to licensing partners and CROs.
  • Provides support as required for licensing activities, regulatory authority inspections audits and for project product recall activities.
  • Collaborates with other departments (e.g., training) to provide expertise and guidance to personnel for interdepartmental and cross-functional team activities, including process improvement standards and metrics.
  • Interacts with service providers as required to address safety queries, share best practices, and discuss new safety regulations.
  • Provides regional support for activities associated with safety compliance, operations, and medical review as needed.
4D Molecular Therapeutics

4D Molecular Therapeutics

View

4D Molecular Therapeutics develops gene therapies aimed at treating serious genetic diseases by delivering specific genetic material to patients' cells. The company utilizes a unique technology called Therapeutic Vector Evolution to create adeno-associated virus (AAV) vectors, which act as delivery vehicles for therapeutic genes targeting affected cells in the body. Unlike many competitors, 4DMT focuses on precision medicine for genetic disorders, including cystic fibrosis, and operates in a specialized biopharmaceutical market. Their goal is to conduct thorough research and clinical trials to ensure the safety and effectiveness of their therapies, ultimately commercializing them through direct sales or partnerships with larger pharmaceutical companies.

Company Stage

IPO

Total Funding

$170.2M

Headquarters

Emeryville, California

Founded

2013

Growth & Insights
Headcount

6 month growth

4%

1 year growth

0%

2 year growth

0%
Simplify Jobs

Simplify's Take

What believers are saying

  • 4DMT secured a $962 million deal with Astellas Pharma for R100 vector technology.
  • Positive Phase 1/2 AEROW trial data for 4D-710 shows promise in cystic fibrosis treatment.
  • Lifting of clinical hold on 4D-310 suggests regulatory progress and pipeline advancement.

What critics are saying

  • Potential competition from CRISPR Therapeutics and Editas Medicine in gene therapy.
  • Reliance on partnerships like Astellas could pose risks if expectations aren't met.
  • Stock price fluctuations from public offerings may impact financial stability.

What makes 4D Molecular Therapeutics unique

  • 4DMT uses proprietary Therapeutic Vector Evolution for advanced AAV vector development.
  • Their R100 vector technology effectively penetrates the internal limiting membrane in eye therapies.
  • 4DMT focuses on aerosolized gene therapies, like 4D-710 for cystic fibrosis lung disease.

Help us improve and share your feedback! Did you find this helpful?

INACTIVE